MONTREAL, Oct. 02, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive agreement with Simovision for distribution rights in the Benelux Union for its patented I-PEN® Tear Osmolarity System.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b57d1da7-65e5-4fce-ae85-104db78d5b1e
The I-PEN® Tear Osmolarity System is the world’s first, handheld platform that offers eye care professionals a quick and reliable tool for screening dry eye patients. It is considered the new standard in diagnosing dry eye disease.
Daniel Hofmann, President of I-MED Pharma stated, “Simovision is a promising partner for us, with a focus on bringing innovative and reliable products to the ophthalmic market. They have a unique vision for expanding access of our cutting-edge products to both eye care professionals and dry eye patients in the Benelux Union. We are excited by the opportunity present in this region and will be working closely with Simovision to launch our I-PEN® Tear Osmolarity System in the upcoming months.”
Marc Simonet, Founder & CEO of Simovision commented, “We are delighted to start working with I-MED Pharma, a company that has an extensive dry eye product offering that will complete our dry eye portfolio. Partnering with I-MED Pharma will also allow for potential opportunities in the surgical field, reinforcing our mission to help our customers achieve optimal and measurable outcomes, so they can make people see, feel and look better.”
About I-MED Pharma
I-MED Pharma Inc. is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established almost thirty years ago, I-MED Pharma creates and distributes innovative medical, surgical and veterinary eye care products worldwide. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degeneration, dry eye, glaucoma and meibomian gland dysfunction.
I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and invests heavily into education and developing effective dry eye products. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, dry eye drops, ocular hygiene, nutrition and therapeutic accessories.
About Simovision
Founded in 2002, Simovision is a partner in ophthalmic solutions for diagnostic equipment, dry eyes and cataract, retina & refractive surgery. As a supplier of high-quality products to private clinics and hospitals, Simovision guarantees flexible service, reliability and expertise, which together form the basis for the company vision. www.simovision.com
For more information, please email media@imedpharma.com or visit imedpharma.com.